This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
by Sundeep Ganoria
Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.
JAZZPositive Net Change ACBPositive Net Change GTBIFPositive Net Change
biotechs marijuana medical
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
by Zacks Equity Research
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth; Halozyme, Akero, Kiniska, ANI and Twist stand out.
HALOPositive Net Change ANIPNegative Net Change KNSANegative Net Change TWSTPositive Net Change AKRONegative Net Change
biotechs
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
by Zacks Equity Research
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
AZNPositive Net Change GSKNegative Net Change BIIBPositive Net Change IONSPositive Net Change
biotechs medical pharmaceuticals
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
by Sundeep Ganoria
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
RDYNegative Net Change TEVAPositive Net Change ALVONegative Net Change
biotechs medical
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
by Zacks Equity Research
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
VRTXPositive Net Change ADPTPositive Net Change CRSPPositive Net Change AKRONegative Net Change
biotechs
AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire
by Zacks Equity Research
AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with nasal polyps.
AZNPositive Net Change MRKNegative Net Change AMGNPositive Net Change
biotechs
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
by Ahan Chakraborty
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
PFEPositive Net Change AMPHPositive Net Change CRMDNegative Net Change MIRMPositive Net Change
biotechnology biotechs medical pharmaceuticals
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
by Ekta Bagri
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
BDTXPositive Net Change CGEMPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector
HALOPositive Net Change ANIPNegative Net Change KNSANegative Net Change TWSTPositive Net Change AKRONegative Net Change
biotechnology biotechs medical pharmaceuticals
Implied Volatility Surging for Eton Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ETON stock based on the movements in the options market lately.
ETONNegative Net Change
biotechnology biotechs medical
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
by Zacks Equity Research
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
REGNNegative Net Change SNYNegative Net Change CRMDNegative Net Change KNSANegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
by Zacks Equity Research
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
SNYNegative Net Change CRMDNegative Net Change KNSANegative Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
by Sundeep Ganoria
FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.
MRKNegative Net Change MRNANegative Net Change SMMTPositive Net Change
biotechs medical pharmaceuticals vaccines
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
by Zacks Equity Research
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
REGNNegative Net Change ADPTPositive Net Change NTLAPositive Net Change AKRONegative Net Change
biotechs
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
by Zacks Equity Research
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
by Ekta Bagri
Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.
BMYPositive Net Change NVONegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
by Zacks Equity Research
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
NVSPositive Net Change QGENPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
by Zacks Equity Research
Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.
GSKNegative Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
by Ekta Bagri
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
ILMNPositive Net Change BEAMPositive Net Change WVEPositive Net Change CRSPPositive Net Change TWSTPositive Net Change WGSPositive Net Change
biotechnology biotechs gene-editing genetics genomics medical pharmaceuticals
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
by Zacks Equity Research
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
by Ahan Chakraborty
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
PFEPositive Net Change AMPHPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
by Sundeep Ganoria
Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.
RDYNegative Net Change TEVAPositive Net Change ALVONegative Net Change
biotechs medical
Biogen Gets EU Nod for First Postpartum Depression Drug
by Zacks Equity Research
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
BIIBPositive Net Change SUPNNegative Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechs medical pharmaceuticals
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
by Zacks Equity Research
GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.
AZNPositive Net Change GSKNegative Net Change JNJNegative Net Change LLYPositive Net Change
biotechs
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
by Zacks Equity Research
Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.
PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs